TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02267681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intravenous fentanyl for sedation/analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: Intravenous alfentanyl for sedation/analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous propofol for sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous propofol for sedation
Study: NCT01465958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GAMUNEX-C
Description: GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
Study: NCT02709980

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Description: The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
Study: NCT02641691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT02267681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous propofol for sedation
Study: NCT03606616

Intervention type: PROCEDURE
Intervention: no further ALND arm
Description: Patients meeting the Z0011 inclusion criteria to receive no additional ALND
Study: NCT02641691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT04992091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: constructive debriefing
Description: Constructive debriefing was applied to an interventional group Traditional debriefing was applied on noninterventional group
Study: NCT05128552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment technique
Description: A self inflating Ambu bag with one way valve , augmentation volume of air within 3 to 4 successive breaths and holding few seconds then coughing
Study: NCT00328367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: aripiprazole augmentation of clozapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03827603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
Study: NCT01584739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8683
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
Study: NCT00437424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
Study: NCT04246658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program
Description: traditional physical therapy program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy program
Description: traditional physical therapy program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training on platform swing walkway
Description: gait training on platform swing walkway for 30 minute.
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa 500 mg capsule x 2 with 240 mL water; single dose
Study: NCT05128552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physiotherapy
Description: Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional chest physiotherapy
Description: Positioning of the patient according the drainage position for each lobe of each lung and applying airway hygiene techniques such as percussion and vibration
Study: NCT00499694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
Study: NCT00499694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satraplatin
Description: 80 mg/m(2), Orally, Days 1-5, every 35 days
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa 500 mg capsule x 2 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa 500 mg capsule x 2 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa 500 mg capsule x 2 with 240 mL water; single dose
Study: NCT02326194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose Ebola Zaire vaccine (Ad5-EBOV)
Description: one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Ebola Zaire vaccine (Ad5-EBOV)
Description: two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (one dose)
Description: placebo, one doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (two doses)
Description: placebo, two doses, with one dose to each arm at a same time.
Study: NCT02104375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (6g/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (6g/day).
Study: NCT02669056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-HT measurement

Intervention type: OTHER
Group type: OTHER
Intervention: 5-HT measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cerebral MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video recording

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: growth curves

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASQ questionnaire
Study: NCT01526850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: mesenchymal stem cell
Description: Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine and Glucocorticoid
Description: Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
Study: NCT03417375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sinus Augmentation
Description: Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Sinus Augmentation
Description: Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
Study: NCT03180788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction assisted ESD
Description: A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ESD
Description: Endoscopic submucosa dissection
Study: NCT04583293

Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any intervention or new treatment.

Intervention type: OTHER
Intervention: No intervention
Description: This study does not involve any intervention or new treatment.
Study: NCT02152111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut flour
Description: Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Patients were instructed to follow the dietary treatment for 6 months.
Study: NCT04527679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC combined Lenvatinib
Description: 1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg).
Study: NCT00202228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cofactor supplementation (thiamine, riboflavin, L-carnitine)
Description: Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apriso 375 mg capsule x 3 with 240 mL water; single dose
Study: NCT03426735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry heat
Description: Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry cold
Description: Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
Study: NCT03586427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 administered orally as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 administered orally as a single tablet
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose
Study: NCT03586427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 administered orally as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-241751
Description: AGN-241751 administered orally as a single tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally as a single tablet
Study: NCT02885831

Intervention type: DEVICE
Intervention: Abduction splintage
Description: Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
Study: NCT04025736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Description: Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
Study: NCT02160184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)
Study: NCT03498963

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchoalveolar lavage
Description: Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
Study: NCT02136446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoGlo Nerve Block Catheter
Description: Catheter used for a paravertebral anesthesia block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pajunk® Nerve Block Catheter
Description: Nerve Block Catheter
Study: NCT01882101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Description: 34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
Study: NCT02477072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose
Study: NCT03044756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Description: Omit Citrotide 0.25 dose on the day of triggering of ovulation
Study: NCT00795392

Intervention type: OTHER
Intervention: ASA scale
Description: ASA scale evaluation before operation
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lialda 1200 mg tablet x 1 with 240 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Study: NCT00795392

Intervention type: OTHER
Intervention: Full-scale psychological assessment
Description: Full-scale psychological evaluation before operation
Study: NCT04362059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COVSurf Drug Delivery System
Description: Device introduces surfactant to the patients lungs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for respiratory illness
Study: NCT02823886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI at D7
Description: The infarct size measured on MRI at 7 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
Study: NCT00379210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training (MMT)
Description: 8-week training course in mindfulness meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education course
Description: 8-week course in nutrition
Study: NCT04301947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard warm-up protocol
Description: Stationary cycling and lower limb stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluteal activation warm-up protocol
Description: Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
Study: NCT00135200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Tositumomab
Description: The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose.
Study: NCT01028976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (ascorbic acid)
Description: 1000 mg/day (two 500-mg tablets), 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (two 500-mg tablets), 8 weeks
Study: NCT00821093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 µg
Description: Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
Study: NCT00741923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: navy beans added to regular diet
Description: 5 cups per week of commercially available white beans for 4-weeks
Study: NCT01133678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
Study: NCT00135226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Study: NCT00135226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Ethyl Esters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Ethyl Esters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Omega-3 Ethyl Esters
Study: NCT01999400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose
Study: NCT00513149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading